The trajectory of companies tied to flagship drugs like Viagra presents a challenging investment scenario . While the initial surge of copyright, fueled by Viagra's remarkable popularity, generated substantial profits , the loss of exclusivity in key markets has introduced considerable risk . Investors are now facing the consequences of generic com